lp-pla2

Lp-PLA2-IN-3 is a potent, orally bioactive lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, effectively inhibiting recombinant human [Lp-PLA2] with an IC50 value of 14 nM.

Lp-PLA2-IN-2 is a selective and potent lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 120 nM for recombinant human Lp-PLA2.

Lp-PLA2-IN-1 (Lp-PLA2 inhibitor 1) suppresses Lp-PLA2 activity processes for their preparation. Lp-PLA2-IN-1 (Lp-PLA2 inhibitor 1) also inhibits to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example, atherosclerosis, Alzheimer's disease.

1-Linoleoyl Glycerol (Monolinolein) is fatty acid glycerol that has been isolated from Saururus Chinensis roots. The (R)-1-Linoleoyl Glycerol and (S)-1-Linoleoyl Glycerol exhibit Lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitory activities with IC50 values of 45.0 and 52.0 μM, respectively.

Rilapladib (SB 659032) is a selective inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2, IC50 = 230 pM) and acts as an antagonist of the platelet-activating factor receptor.

Darapladib (SB-480848) is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor with an IC50 value of 0.25 nM, which can exert cardiovascular protective effects [1,3].

SB-435495 is an orally active, selective and potent Lp-PLA2 inhibitor (IC50 of 0.06 nM) for the study of autoimmune uveitis and atherosclerosis.

Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) with potential applications in diseases associated with Lp-PLA2 activity [e.g., atherosclerosis, Alzheimer's disease].

Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), formerly known as platelet-activating factor acetylhydrolase (PAF-AH). This enzyme catalyzes the hydrolysis of lipoprotein lipids or phospholipids. The compound has research potential in neurodegenerative diseases such as Alzheimer's disease (AD), as well as glaucoma, age-related macular degeneration (AMD), and cardiovascular diseases like atherosclerosis[1].

Lp-PLA2-IN-4 is a potent lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor and an inhibitor of platelet-activating factor acetylhydrolase (PAF-AH), a phospholipase A2 involved in lipoprotein lipid or phospholipid hydrolysis. Lp-PLA2-IN-4 has potential for study in diseases associated with Lp-PLA2 activity, such as Alzheimer's disease and atherosclerosis. [Compound 38]

Lp-PLA2-IN-5 is a potent lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor and an inhibitor of platelet-activating factor acetylhydrolase (PAF-AH), a phospholipase A2 involved in lipoprotein lipid or phospholipid hydrolysis. Lp-PLA2-IN-5 (Compound 35) may have potential applications in studying diseases linked to Lp-PLA2 activity, including Alzheimer's disease and atherosclerosis.

Lp-PLA2-IN-6 is a tetracyclic pyrimidinone compound that is a potent inhibitor of Lp-PLA2 and is able to act on rhLp-PLA2 (pIC50: 10.0). lp-PLA2-IN-6 has shown research potential in neurodegenerative diseases.

Lp-PLA2-IN-9 (compound 17) is a tetracyclic pyrimidinone compound and a potent inhibitor of Lp-PLA2, targeting rhLp-PLA2 with a pIC50 of 10.1, and has demonstrated research potential in neurodegenerative diseases.

Lp-PLA2-IN-13 (compound 15), a potent Lp-PLA2 inhibitor, shows promise for neurodegenerative disease research [1].

Lp-PLA2-IN-14 (Compound 19), an inhibitor of rhLp-PLA2, exhibits a potent inhibitory effect with a pIC50 value of 8.4 and is applicable in research on neurodegenerative disorders including Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD), and cardiovascular diseases such as atherosclerosis [1].

Lp-PLA2-IN-17 (Compound 39) acts as an inhibitor of Lp-PLA 2. It is utilized in research to explore disorders associated with the hydrolysis of oxidized lipids into two inflammatory substances mediated by Lp-PLA 2 [1].

Darapladib-impurity is the impurity of Darapladib. Darapladib inhibits lipoprotein-associated phospholipase A2 (Lp-PLA2).

GSK2647544 is an orally active selective inhibitor of Lp-PLA2, a calcium non-dependent phospholipase A2 secreted primarily by monocyte-derived macrophages that exhibits pro-inflammatory effects.

SB-435495 hydrochloride is a potent, selective, reversible, non-covalent, and orally active inhibitor of Lp-PLA2, with an IC50 of 0.06 nM [1] [3].

SB-435495 ditartrate is a potent, selective, reversible, non-covalent, and orally active Lp-PLA2 inhibitor with an IC50 of 0.06 nM [1] [3].

Ergosterol peroxide exhibits anti-cancer, amoebicidal, anticomplementary, antibacterial, antiviral, anti-oxdiant, and anti-melanogenic activities. Ergosterol peroxide could as an anti-atherosclerosis agent, it exhibits hACAT-1 and Lp-PLA2 inhibitory effec